A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in
a part of your body like your lungs or liver instead of your blood. Once tumors have grown
bigger in one place but haven't spread, they're called locally advanced. If your cancer has
spread to other parts of your body, it's called metastatic. When a cancer has gotten so big
it can't easily be removed or has spread to other parts of the body, it is called
unresectable. These types of cancer are harder to treat.
Patients in this study must have cancer that has come back or did not get better with
treatment. Patients must have a solid tumor cancer that can't be treated with standard of
care drugs.
This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of
antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them.
They may also stick to some normal cells.
This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are
hard to treat or have spread throughout the body.
This study will have 3 parts. Part A and Part B of the study will find out how much
SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A
and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.